InvestorsHub Logo
Followers 17
Posts 581
Boards Moderated 0
Alias Born 05/18/2018

Re: None

Thursday, 02/11/2021 6:54:44 PM

Thursday, February 11, 2021 6:54:44 PM

Post# of 461470
A few more CC comments, not seen here:

Positioning 3-71 for Frontal Temporal Dementia, so it won't compete with 2-73. Good move!

3-71 trial challenge is to ascend to max dose. Dr.M said this went very well, no problems. Good!

3-71 trial results expected much earlier than June. Good!

LOTS to be discussed with FDA this year. Good!

FragileX preclinical data to be packaged and published soon. Ok soon.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News